The effects of antifungal therapy on XXXX and @entity5929 .

@entity1 @entity364 @entity358 @entity5929 @entity230 @entity288
BACKGROUND AND OBJECTIVE: Very little is known about the response rates to or appropriateness of treatment for @entity1 with @entity358 . This study assessed the effect of antifungal therapy in @entity1 with @entity364 ( @entity364 ) and @entity5929 ( @entity5929 ). METHODS: A retrospective cohort study of 33 adult @entity1 who fulfilled the criteria for either @entity364 (n = 22) or @entity5929 (n = 11) was conducted. All @entity1 had received antifungal therapy for at least 6 months. The primary study end point was the effect of antifungal therapy on @entity1 ' lung function. RESULTS: Overall, total IgE values and radioallergosorbent test (RAST) for A. fumigatus markedly decreased after 6 months of therapy in both @entity364 and @entity5929 @entity1 (P = 0.004 and P = 0.005, respectively). Reduction was seen in the eosinophil count (P = 0.037), dose of oral @entity230 (P = 0.043) and courses of systemic @entity230 required (P = 0.041). Lung function also improved (P = 0.016). Four of 10 @entity1 discontinued oral @entity230 after 6 months of therapy. Reduction in IgE levels (P = 0.015) and RAST for A. fumigatus was also observed (P = 0.006) for those @entity1 treated for at least 1 year with antifungal drugs. CONCLUSIONS: Both @entity5929 and @entity364 @entity1 benefited from oral antifungal therapy. The antifungal therapy may act by reducing the antigenic load, interacting with @entity288 or by a direct immunological effect.
